Who are Ch14.18's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DANYELZA, DANYELZA, monoclonal antibody Ch14.18, monoclonal antibodies GD2, Ch14.18/CHO, Hu3F8.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dinutuximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Ch14.18 — Competitive Intelligence Brief

Ch14.18 (DINUTUXIMAB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glycolipid Disialoganglioside-directed Antibody [EPC]. Area: Oncology.

marketed Glycolipid Disialoganglioside-directed Antibody [EPC] GD2 Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Ch14.18 (DINUTUXIMAB) — United Therap. Dinutuximab binds to GD2 on neuroblastoma cells and induces cell lysis via ADCC and CDC.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ch14.18 TARGET	DINUTUXIMAB	United Therap	marketed	Glycolipid Disialoganglioside-directed Antibody [EPC]	GD2	2015-01-01
DANYELZA	NAXITAMAB-GQGK	Y-MABS THERAPEUTICS INC	marketed	Glycolipid Disialoganglioside-directed Antibody [EPC]	GD2
DANYELZA	DANYELZA	Memorial Sloan Kettering Cancer Center	marketed	GD2-targeting monoclonal antibody	GD2 (disialoganglioside)
monoclonal antibody Ch14.18	monoclonal antibody Ch14.18	National Cancer Institute (NCI)	phase 3	Monoclonal antibody	GD2
monoclonal antibodies GD2	monoclonal antibodies GD2	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	phase 3	Monoclonal antibody	GD2
Ch14.18/CHO	Ch14.18/CHO	University Hospital Southampton NHS Foundation Trust	phase 3	Monoclonal antibody (GD2-targeting immunotherapy)	GD2 (disialoganglioside)
Hu3F8	NAXITAMAB	Y-Mabs Therapeutics Inc	marketed	Glycolipid Disialoganglioside-directed Antibody [EPC]		2020-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glycolipid Disialoganglioside-directed Antibody [EPC] class)

United Therap · 1 drug in this class
Y-MABS THERAPEUTICS INC · 1 drug in this class
Y-Mabs Therapeutics Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ch14.18 — Competitive Intelligence Brief. https://druglandscape.com/ci/dinutuximab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab